Impact of antidiabetic treatment with dipeptidyl peptidase-4 inhibitors on the risk of cardiac arrhythmias among patients with type 2 diabetes mellitus

被引：0
|
作者：
Boulmpou, A. [1 ]
Patoulias, D. [2 ]
Teperikidis, E. [1 ]
Tsavousoglou, C. [1 ]
Vergopoulos, S. [1 ]
Toumpourleka, M. [1 ]
Doumas, M. [2 ]
Fragakis, N. [1 ]
Vassilikos, V. [1 ]
Papadopoulos, C. E. [1 ]
机构：
[1] Hippokrat Gen Hosp Thessaloniki, Dept Cardiol 3, Thessaloniki, Greece
[2] Hippokrat Gen Hosp Thessaloniki, Propedeut Dept Internal Med 2, Thessaloniki, Greece
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2955 / 2955
页数：1
相关论文
共 50 条
  • [21] Impact of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: a network meta-analysis
    Yang, Jun
    Wu, Shanshan
    Xu, Yang
    Cai, Ting
    Yang, Zhirong
    Zhan, Siyan
    Sun, Feng
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (SUPP 2) : 4 - 5
  • [22] Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
    Carolyn F. Deacon
    Nature Reviews Endocrinology, 2020, 16 : 642 - 653
  • [23] Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Neumiller, Joshua J.
    Campbell, R. Keith
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) : 1515 - 1525
  • [24] Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Johnson, Kathryn M. S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (04) : 455 - 463
  • [25] Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
    Deacon, Carolyn F.
    NATURE REVIEWS ENDOCRINOLOGY, 2020, 16 (11) : 642 - 653
  • [26] Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
    Kaneko, Masayuki
    Narukawa, Mamoru
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 116 : 171 - 182
  • [27] DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES
    Chen, W. S.
    Chang, Y. S.
    Tsai, C. Y.
    Chang, C. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1246 - 1247
  • [28] SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    Lizan, L.
    Aceituno, S.
    Franch, J.
    Perez, A.
    Granell, M.
    Fuster, E.
    VALUE IN HEALTH, 2014, 17 (07) : A348 - A348
  • [29] Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
    Meng, Jie
    Yan, Rui
    Zhang, Chen
    Bai, Xueyan
    Yang, Xingsheng
    Yang, Yu
    Feng, Tao
    Liu, Xin
    LIPIDS IN HEALTH AND DISEASE, 2023, 22 (01)
  • [30] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
    Herman, G. A.
    Stein, P. P.
    Thornberry, N. A.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 761 - 767
12345